Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy

The anti-CD20-specific monoclonal antibody rituximab (RTX), in combination with chemotherapy, is commonly used for primary treatment in chronic lymphocytic leukemia (CLL). However, relapses remain important and activation of the complement pathway is one of the mechanisms by which RTX generates the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Bordron, Anne, Bagacean, Cristina, Mohr, Audrey, Tempescul, Adrian, Bendaoud, Boutahar, Deshayes, Stéphanie, Dalbies, Florence, Buors, Caroline, Saad, Hussam, Berthou, Christian, Pers, Jacques-Olivier, Renaudineau, Yves
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6114972/
https://ncbi.nlm.nih.gov/pubmed/30167081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25657
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares